Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Drugs in Development News & Deals for Amlodipine Besylate

    Client Email Product

    Amlodipine Besylate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    107
    US DMFs Filed

    US DMFs Filed

    41
    CEP/COS Certifications

    CEP/COS Certifications

    42
    JDMFs Filed

    JDMFs Filed

    25
    Other Certificates

    Other Certificates

    27
    Other Suppliers

    Other Suppliers

    49
    API REF. PRICE (USD / KG)
    117

    API Market Place

    35
    INTERMEDIATES
    11
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    420
    Europe

    Europe

    111
    Canada

    Canada

    134
    Australia

    Australia

    9
    South Africa

    South Africa

    35
    Uploaded Dossiers

    Uploaded Dossiers

    129
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    3,085.00

    Annual Reports

    1,396.00

    FDF Market Place

    7
    EXCIPIENTS
    335
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    31

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    5

    News

    39
    REF STANDARD

    EDQM

    5

    USP

    1

    JP

    7

    Other Listed Suppliers

    1
    SERVICES

    0

    left grey arrow
    right gray arrow
    • TABLET;ORAL - EQ 10MG BASE
    • TABLET;ORAL - EQ 2.5MG BASE
    • TABLET;ORAL - EQ 5MG BASE
    • CAPSULE;ORAL - EQ 10MG BASE;20MG
    • CAPSULE;ORAL - EQ 10MG BASE;40MG
    • CAPSULE;ORAL - EQ 2.5MG BASE;10MG
    • CAPSULE;ORAL - EQ 5MG BASE;10MG
    • CAPSULE;ORAL - EQ 5MG BASE;20MG
    • CAPSULE;ORAL - EQ 5MG BASE;40MG
    • TABLET;ORAL - EQ 10MG BASE;14MG
    • TABLET;ORAL - EQ 2.5MG BASE;3.5MG
    • TABLET;ORAL - EQ 5MG BASE;7MG
    • TABLET;ORAL - EQ 10MG BASE;200MG
    • TABLET;ORAL - EQ 2.5MG BASE;200MG
    • TABLET;ORAL - EQ 5MG BASE;200MG
    • TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE
    • TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE
    • TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE
    • TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE
    • TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE
    • TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE
    • TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE
    • TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE
    • TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE
    • TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE
    • TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE
    • TABLET;ORAL - EQ 10MG BASE;160MG
    • TABLET;ORAL - EQ 10MG BASE;320MG
    • TABLET;ORAL - EQ 5MG BASE;160MG
    • TABLET;ORAL - EQ 5MG BASE;320MG
    • TABLET;ORAL - EQ 10MG BASE;20MG
    • TABLET;ORAL - EQ 10MG BASE;40MG
    • TABLET;ORAL - EQ 5MG BASE;20MG
    • TABLET;ORAL - EQ 5MG BASE;40MG
    • TABLET;ORAL - EQ 10MG BASE;12.5MG;160MG
    • TABLET;ORAL - EQ 10MG BASE;25MG;160MG
    • TABLET;ORAL - EQ 10MG BASE;25MG;320MG
    • TABLET;ORAL - EQ 5MG BASE;12.5MG;160MG
    • TABLET;ORAL - EQ 5MG BASE;25MG;160MG
    • TABLET;ORAL - EQ 10MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 10MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 5MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - EQ 5MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CMP Pharma, Inc Announces that Norliqva®, the First and Only FDA-approved Liquid Solution of Amlodipine, is Now Available

    Details:

    Norliqva (Amlodipine) oral solution, 1 mg/mL, first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, for treatment of hypertension in patients 6 years of age and older.


    Lead Product(s): Amlodipine Besylate

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Norliqva

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights

    Details:

    The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hypertension).


    Lead Product(s): Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Midas Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership December 14, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Burke Therapeutics, LLC Signs Exclusive US Marketing and Supply Agreement

    Details:

    Burke will market the fixed-dose combination drug, Consensi to lower blood pressure, and celecoxib for the management of the signs and symptoms of osteoarthritis.


    Lead Product(s): Amlodipine Besylate,Celecoxib

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Coeptis Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement March 11, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search